MHRA's 2026-2030 patient involvement plan: what it could mean for PV teams

What MHRA has published

On 5 November 2026 the MHRA published its patient and public involvement and engagement plan for 2026-2030. The corporate plan sets out how patients, carers and the public will be involved in the regulator's decisions. It builds on the 2021-2025 strategy.

The summary available to us does not describe specific commitments, such as new committee seats, consultation mechanisms, timelines or measures tied to pharmacovigilance. We therefore cannot say whether the plan changes how safety reports, signals or risk-minimisation measures are handled. The commitments are the first thing to check in the full document. Until then, this article is an analysis of where such a plan could matter, not a description of what it requires.

Why pharmacovigilance is the natural test bed

Safety regulation is where the regulator's decisions most directly change what patients and carers do day to day. Monitoring schedules, restrictions, warnings and withdrawals all land on people who live with the consequences. A plan to involve patients in regulatory decisions will be judged partly on whether it reaches this part of the system.

The MHRA's own Drug Safety Update from the same day shows the point. The agency issued interim advice on Duvyzat (givinostat) after international reports of deaths in patients with Duchenne muscular dystrophy (DMD). It proposes more frequent ECG and electrolyte checks. Implementation is subject to an ongoing independent review, and no deaths have been reported in the UK. Families affected by DMD will care about how monitoring is explained, how burdensome extra checks are, and how the review's outcome is communicated. The records do not say whether patient input fed into this advice, so we make no claim either way.

A week of contrasting regulatory signals

The other records from the same days show the range of safety communication a patient-involvement approach would have to cover.

At the serious end, the US FDA's CBER is investigating postmarketing malignancy reports linked to Zolgensma. It cites confirmed AAV vector insertional oncogenesis involving GLI1 and says the neoplasia risk applies to both onasemnogene abeparvovec products, Zolgensma and Itvisma. CBER is assessing whether regulatory action is needed, and the outcome is not yet known. Gene therapy decisions involve long-term risk and benefit trade-offs that patients and carers are well placed to weigh.

At the routine end, the EMA published two PSUSA outcomes: diethylamine-salicylate/escin and ethinylestradiol/gestodene. Both ended in maintenance of the marketing authorisations. These are procedural results that rarely prompt public discussion, though they are still part of the safety record that patients depend on.

The EMA also released a Q&A for marketing authorisation holders and applicants on the CHMP opinion in the nitrosamine impurities referral (EMEA-H-A5(3)-1490). That is a technical, industry-facing document. It is a reminder that much of PV and quality work happens far from patients' view.

Two further records bear on transparency. The Dutch inspectorate IGJ published a report on a January 2026 visit to Crinetics Pharmaceuticals Europe GmbH in Amsterdam. The available material does not disclose findings, required measures or the type of inspection. In Spain, AEMPS warned of a double-failure risk in certain Likorall ceiling patient lifts, where a motor shaft break combined with a faulty Single Fault Safety system could cause falls or sudden descents. Baxter is inspecting affected units. That is a device issue rather than a medicines one, but it shows the plain-language, action-oriented communication that patients and carers need.

Who is affected

QPPVs and PV teams with UK-authorised products are the most directly affected. The plan sets expectations for how the regulator engages with the public. Companies may find that safety communications, risk-minimisation materials and signal-related outreach are read against the same expectation of accessibility and openness.

Teams working on rare-disease and advanced-therapy products should pay particular attention. Patient communities are small and well organised, and they follow safety developments closely. The Duvyzat and Zolgensma cases show how quickly a safety concern can become a community concern.

Quality and compliance staff should note the IGJ example. Publication of an inspection report with no accessible findings shows the gap between transparency in form and transparency in substance. How the MHRA fills that gap in its own processes is a question the plan may answer.

What to watch

First, read the plan itself for concrete commitments: which decisions are covered, how people are recruited, and whether safety-related processes are included. Second, watch how the MHRA communicates the outcome of the independent Duvyzat review and whether the interim monitoring advice is implemented. Third, follow CBER's assessment of Zolgensma and Itvisma and whether other regulators, including the MHRA, respond. None of these outcomes is known yet.

Fourth, track whether the plan produces measurable outputs over its five-year span. A plan is only as useful as its follow-through, and 2021-2025 provides a baseline for judging it.